Literature DB >> 22816437

Cervical cancer trends in the United States: a 35-year population-based analysis.

Olusola Adegoke1, Shalini Kulasingam, Beth Virnig.   

Abstract

PURPOSE: To analyze trends in invasive cervical cancer incidence by age, histology, and race over a 35-year period (1973-2007) in order to gain insight into changes in the presentation of cervical cancer.
METHODS: Data from the nine Surveillance, Epidemiology, and End Results (SEER) registries that continuously collected information on invasive cervical cancer were analyzed for trends. Standardized to the 2000 U.S population, annual age-adjusted incidence rates were estimated by race and histologic subtype. Histologic subtype was classified into squamous, adenocarcinoma, and adenosquamous.
RESULTS: Overall incidence rates for invasive cervical cancer decreased by 54% over the 35 years, from 13.07/100,000 (1973-1975) to 6.01/100,000 (2006-2007), and the incidence rates declined by 51% and 70.2%, respectively, among whites and blacks. The incidence rates for squamous carcinoma decreased by 61.1% from 10.2/100,000 (1973-1975) to 3.97/100,000 (2006-2007). Incidence rates for adenosquamous cell carcinomas decreased by 16% from 0.27/100,000 (1973-1975) to 0.23/100,000 (2006-2007), and incidence rates for adenocarcinomas increased by 32.2% from 1.09/100,000 (1973-1975) to 1.44/100,000 (2006-2007). This increase in adenocarcinomas was due to an increase in incidence in white women; a decrease in incidence was observed for black women.
CONCLUSIONS: Although marked reductions in the overall and race-specific incidence rates of invasive cervical cancer have been achieved, they mask important variation by histologic subtype. These findings suggest that alternatives to Pap smear-based screening, such as human papillomavirus (HPV) testing and HPV vaccination, need to be prioritized if adenocarcinomas of the cervix are to be controlled.

Entities:  

Mesh:

Year:  2012        PMID: 22816437      PMCID: PMC3521146          DOI: 10.1089/jwh.2011.3385

Source DB:  PubMed          Journal:  J Womens Health (Larchmt)        ISSN: 1540-9996            Impact factor:   2.681


  27 in total

1.  The Icelandic and Nordic cervical screening programs: trends in incidence and mortality rates through 1995.

Authors:  K Sigurdsson
Journal:  Acta Obstet Gynecol Scand       Date:  1999-07       Impact factor: 3.636

2.  Screening for cervical cancer: recommendations and rationale.

Authors: 
Journal:  Am J Nurs       Date:  2003-11       Impact factor: 2.220

3.  HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica.

Authors:  M Schiffman; R Herrero; A Hildesheim; M E Sherman; M Bratti; S Wacholder; M Alfaro; M Hutchinson; J Morales; M D Greenberg; A T Lorincz
Journal:  JAMA       Date:  2000-01-05       Impact factor: 56.272

4.  Trends in contraceptive use in the United States: 1982-1995.

Authors:  L J Piccinino; W D Mosher
Journal:  Fam Plann Perspect       Date:  1998 Jan-Feb

5.  Prevalence and trends in oral contraceptive use in premenopausal females ages 12-54 years, United States, 1971-80.

Authors:  R Russell-Briefel; T Ezzati; J Perlman
Journal:  Am J Public Health       Date:  1985-10       Impact factor: 9.308

6.  Cancer statistics, 2012.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2012-01-04       Impact factor: 508.702

7.  The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States--a 24-year population-based study.

Authors:  H O Smith; M F Tiffany; C R Qualls; C R Key
Journal:  Gynecol Oncol       Date:  2000-08       Impact factor: 5.482

8.  Mortality trends for cervical squamous and adenocarcinoma in the United States. Relation to incidence and survival.

Authors:  Mark E Sherman; Sophia S Wang; Joseph Carreon; Susan S Devesa
Journal:  Cancer       Date:  2005-03-15       Impact factor: 6.860

Review 9.  FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina.

Authors:  C L Kosary
Journal:  Semin Surg Oncol       Date:  1994 Jan-Feb

10.  Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000.

Authors:  Sophia S Wang; Mark E Sherman; Allan Hildesheim; James V Lacey; Susan Devesa
Journal:  Cancer       Date:  2004-03-01       Impact factor: 6.860

View more
  81 in total

1.  Improving the Utilization of Human Papillomavirus and Cervical Cytology Co-testing for Cervical Cancer Screening in an Obstetrics and Gynecology Resident Clinic.

Authors:  Kurt Yoshino; Maxine Karimoto; Christina Marzo; Bliss Kaneshiro; Mark Hiraoka
Journal:  Hawaii J Med Public Health       Date:  2015-08

Review 2.  Human Papillomavirus Laboratory Testing: the Changing Paradigm.

Authors:  Eileen M Burd
Journal:  Clin Microbiol Rev       Date:  2016-04       Impact factor: 26.132

3.  A birth cohort analysis of the incidence of adenocarcinoma of the uterine cervix in the USA.

Authors:  Cairong Zhu; Bryan A Bassig; Yawei Zhang; Kunchong Shi; Peter Boyle; Ni Li; Tongzhang Zheng
Journal:  Eur J Cancer Prev       Date:  2015-05       Impact factor: 2.497

4.  Disparity in the persistence of high-risk human papillomavirus genotypes between African American and European American women of college age.

Authors:  Carolyn E Banister; Amy R Messersmith; Bo Cai; Lisa B Spiryda; Saundra H Glover; Lucia Pirisi; Kim E Creek
Journal:  J Infect Dis       Date:  2014-07-15       Impact factor: 5.226

Review 5.  Clinical application of DNA ploidy to cervical cancer screening: A review.

Authors:  David Garner
Journal:  World J Clin Oncol       Date:  2014-12-10

6.  Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening.

Authors:  Mark Schiffman; Walter K Kinney; Li C Cheung; Julia C Gage; Barbara Fetterman; Nancy E Poitras; Thomas S Lorey; Nicolas Wentzensen; Brian Befano; John Schussler; Hormuzd A Katki; Philip E Castle
Journal:  J Natl Cancer Inst       Date:  2018-05-01       Impact factor: 13.506

Review 7.  The Surveillance, Epidemiology, and End Results (SEER) Program and Pathology: Toward Strengthening the Critical Relationship.

Authors:  Máire A Duggan; William F Anderson; Sean Altekruse; Lynne Penberthy; Mark E Sherman
Journal:  Am J Surg Pathol       Date:  2016-12       Impact factor: 6.394

8.  Immunophenotype analysis using CLDN18, CDH17, and PAX8 for the subcategorization of endocervical adenocarcinomas in situ: gastric-type, intestinal-type, gastrointestinal-type, and Müllerian-type.

Authors:  Shiho Asaka; Tomoyuki Nakajima; Kaori Kugo; Risako Kashiwagi; Nozomi Yazaki; Tsutomu Miyamoto; Takeshi Uehara; Hiroyoshi Ota
Journal:  Virchows Arch       Date:  2020-01-13       Impact factor: 4.064

Review 9.  Practical issues related to uterine pathology: in situ and invasive cervical glandular lesions and their benign mimics: emphasis on cytology-histology correlation and interpretive pitfalls.

Authors:  David C Wilbur
Journal:  Mod Pathol       Date:  2016-01       Impact factor: 7.842

10.  Temporal trends in the epidemiology of cervical cancer in South Africa (1994-2012).

Authors:  Gbenga Olorunfemi; Ntombizodwa Ndlovu; Gwinyai Masukume; Admire Chikandiwa; Pedro T Pisa; Elvira Singh
Journal:  Int J Cancer       Date:  2018-08-07       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.